Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via FcγRIIa

被引:4
作者
Kannicht, Christoph [1 ]
Danssmann, Ilona [1 ]
Weilandt, Constanze [1 ]
Derkow, Katja [1 ]
Kohla, Guido [1 ]
Geyer, Henriette [1 ]
机构
[1] Octapharma Biopharmaceut GmbH, Mol Biochem, Walther Nernst Str 3, D-12489 Berlin, Germany
关键词
RECOMBINANT FACTOR-VIII; VON-WILLEBRAND-FACTOR; ANTIINFLAMMATORY ACTIVITY; PROLONGED ACTIVITY; RECEPTORS; IMMUNOGENICITY; MATURATION; IGG; REGULATORS; MANAGEMENT;
D O I
10.1097/HS9.0000000000000330
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study compares the effect of recombinant Factor VIII Fc fusion protein (rFVIII-Fc) with recombinant FVIII (rFVIII) on monocyte-derived dendritic cells (moDC's). Cells treated with rFVIII-Fc showed morphological changes typical for cell activation, had a significant up-regulation of cell activation markers and produced higher levels of pro-inflammatory cytokines. Even after stimulation with Lipopolysaccharides, the addition of rFVIII-Fc led to increased expression of activation markers, indicating that rFVIII-Fc is capable of amplifying the maturation signal. On the contrary, cultivation of moDC's with rFVIII did not alter cell morphology or increase surface activation marker expression and pro-inflammatory cytokine production. The binding of the Fc domain to the activating Fc gamma receptor IIa (Fc gamma RIIa) can cause cell activation. Therefore, the effect of rFVIII-Fc on Fc gamma RIIa was analyzed in detail. Cultivation of moDC's with rFVIII-Fc led to increased phosphorylation of Fc gamma RIIa, which was not detected for rFVIII. Blocking Fc gamma RIIa prior to the cultivation with rFVIII-Fc significantly reduced the activating effect of rFVIII-Fc, indicating that rFVIII-Fc-induced moDC activation was caused by Fc gamma RIIa. Moreover, rFVIII-Fc bound to FCGR2A-transfected human embryonic kidney 293 cells. Taken together, our data present a new mechanism of moDC activation by rFVIII-Fc via Fc gamma RIIa.
引用
收藏
页数:14
相关论文
共 57 条
[1]   Dendritic cell-based therapeutic cancer vaccines: past, present and future [J].
Ahmed, Md Selim ;
Bae, Yong-Soo .
CLINICAL AND EXPERIMENTAL VACCINE RESEARCH, 2014, 3 (02) :113-116
[2]   Identification of a receptor required for the anti-inflammatory activity of IVIG [J].
Anthony, Robert M. ;
Wermeling, Fredrik ;
Karlsson, Mikael C. I. ;
Ravetch, Jeffrey V. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (50) :19571-19578
[3]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[4]   Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia [J].
Blumberg, Richard S. ;
Lillicrap, David .
BLOOD, 2018, 131 (20) :2205-2214
[5]   Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions [J].
Boruchov, AM ;
Heller, G ;
Veri, MC ;
Bonvini, E ;
Ravetch, JV ;
Young, JW .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) :2914-2923
[6]   Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency [J].
Bovenschen, N ;
Herz, J ;
Grimbergen, JM ;
Lenting, PJ ;
Havekes, LM ;
Mertens, K ;
van Viijmen, BJM .
BLOOD, 2003, 101 (10) :3933-3939
[7]   Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses [J].
Bruhns, Pierre ;
Iannascoli, Bruno ;
England, Patrick ;
Mancardi, David A. ;
Fernandez, Nadine ;
Jorieux, Sylvie ;
Daeron, Marc .
BLOOD, 2009, 113 (16) :3716-3725
[8]   Determination of disulfide structure in agouti-related protein (AGRP) by stepwise reduction and alkylation [J].
Bures, EJ ;
Hui, JO ;
Young, Y ;
Chow, DT ;
Katta, V ;
Rohde, MF ;
Zeni, L ;
Rosenfeld, RD ;
Stark, KL ;
Haniu, M .
BIOCHEMISTRY, 1998, 37 (35) :12172-12177
[9]   Dendritic cells: The bare bones of immunity [J].
Burns, S ;
Thrasher, AJ .
CURRENT BIOLOGY, 2004, 14 (22) :R965-R967
[10]  
Carter LL, 2002, EUR J IMMUNOL, V32, P634, DOI 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO